Clinical Trial

A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-10.
Status change: Recruiting → Completed 2026-06-28
Trial Details
NCT Number NCT07279636
Lead Sponsor AlphaMol Science Ltd. (Shanghai)
Conditions Healthy Volunteers
Enrollment 55 participants
Start Date 2025-07-21
Primary Completion 2026-02-14 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-30